Fulltext present in this item

Thumbnail
Fulltext: 48539.pdf
Format: PDF
Description: publisher's version
Embargo: until further notice
Title: Role of the inhibitory quotient in HIV therapy.
Author(s): Hoefnagel, J.G.; Koopmans †, P.P. ; Burger, D.M. ; Schuurman, R.; Galama, J.M.D.
Publication year: 2005
Source: Antiviral Therapy, vol. 10, iss. 8, (2005), pp. 879-892
ISSN: 1359-6535
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/48539   http://hdl.handle.net/2066/48539

Display more details
Subject: EBP 3: Effective Primary Care and Public Health
N4i 1: Pathogenesis and modulation of inflammation
N4i 2: Invasive mycoses and compromised host
N4i 3: Poverty-related infectious diseases
NCEBP 13: Infectious diseases and international health
NCMLS 1: Infection and autoimmunity
UMCN 3.2: Cognitive neurosciences
UMCN 4.1: Microbial pathogenesis and host defense
Organization: Internal Medicine
Clinical Pharmacy
Medical Microbiology
Journal title:
Antiviral Therapy
Volume: vol. 10
Issue: iss. 8
Page start: p. 879
Page end: p. 892
Abstract:
A systemic review is presented of all studies that have evaluated the inhibitory quotient (IQ). The IQ is defined as the ratio between (trough) drug concentration and level of drug resistance of the HIV isolate. From the studies presented, it can be concluded that for protease inhibitors (PIs) and efavirenz, the phenotypic IQ is associated with virological response. The genotypic IQ (GIQ) for PIs was also demonstrated to be associated with virological response. An intrinsic limitation of the GIQ is that it is only applicable for PIs, of which resistance is based on the cumulative effect of mutations. As the IQ can be modified by adjustment of the drug dosage, it may be of clinical value. Its application in patient care should therefore be further investigated.

This item appears in the following Collection(s)

Browse

Statistics